Histone deacetylase inhibitors (HDIs) are approved for treating hematologic cancers and are currently being evaluated in hundreds of clinical trials for various cancers and other diseases, although ...
Histone deacetylase inhibitors (HDIs) have progressed rapidly from the laboratory to clinical testing as novel anticancer agents, culminating in the approval of SAHA (Vorinostat, Merck, Whitehouse ...
Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends Patients starting a new anticancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results